Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology.

2018

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439731/

Smith R, Wibom M, Pawlik D, Englund E, Hansson O.

JAMA Neurol. 2019 Mar; 76(3): 310–31

2024 Individualized, cross-validated prediction of future dementia using cognitive assessments in people with mild cognitive symptoms.
2024 Biological mechanisms of resilience to tau pathology in Alzheimer’s disease.
2024 Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer’s disease.
2024 Considerations for widespread implementation of blood-based biomarkers of Alzheimer’s disease.
2024 Recommendations for clinical implementation of blood-based biomarkers for Alzheimer’s disease.
2024 Dementia in Down syndrome
2024 Cerebrovascular disease is associated with Alzheimer’s plasma biomarker concentrations in adults with Down syndrome.
2024 A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer’s Disease.
2024 Association of in vivo retention of [18f] flortaucipir pet with tau neuropathology in corresponding brain regions.
2024 Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer’s disease.
2024 Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease.
2024 Associations between misfolded alpha-synuclein aggregates and Alzheimer’s disease pathology in vivo.
2024 Proteomic changes in Alzheimer’s disease associated with progressive Aβ plaque and tau tangle pathologies.
2024 The Alzheimer’s Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study.
2024 The CentiMarker Project: Standardizing Quantitative Alzheimer’s disease Fluid Biomarkers for Biologic Interpretation